TABLE 1.

Description of cohort by trial enrollment status

	Overall		Not enrolled		Enrolled
	n	(%)	n	(%)	n	(%)	Pa
Total cohort	274	100	122	45.5	152	55.5	-
Age (mean, median [range])	7.4, 5.2 [1.2–20.0]		7.9, 5.6 [1.6–20.0]		6.9, 4.8 [1.2–19.0]		0.11
Age <15	238	87.0	103	84.4	135	88.8	0.26
Age ≥15	36	13.1	19	15.6	17	11.2
Sex
Female	135	49.3	61	50.0	74	48.7	0.83
Male	139	50.7	61	50.0	78	51.3
Ethnicity
Not-Hispanic	78	28.5	28	23.0	50	32.9	0.07
Hispanic	196	71.5	94	77.0	102	67.1
Down syndrome
Not Down syndrome	267	97.4	119	97.5	148	97.4	1.00
Down syndrome	7	2.6	3	2.5	4	2.6
NCI/Rome risk
SR	167	60.9	74	60.7	93	61.2	0.93
HR	107	39.1	48	39.3	59	38.8
Presenting WBC (max)
WBC (mean, median [range])	39.1, 9.0 [0.3–771.8]		36.3, 8.3 [0.3–771.8]		41.2, 11.5 [0.8–562]		0.43
WBC <50 K/μl	222	81.0	100	82.0	122	80.3	0.72
WBC ≥50 K/μl	52	19.0	22	18.0	30	19.7
CNS status
CNS1	244	89.1	108	88.5	136	89.5	0.38
CNS2	28	10.2	14	11.5	14	9.2
CNS3	2	0.7	0	0	2	1.3
Cytogenetic Categoryb
Average	157	57.3	79	64.8	78	51.3	0.02
Favorable	113	41.2	43	35.2	70	46.1
Unfavorable	4	1.5	0	0	4	2.6
EOI MRD
<0.01%	165	60.2	66	54.1	99	65.1	0.15
≥0.01%	40	14.6	22	18.0	18	11.8
Unknown	69	25.2	34	27.9	35	22.7
For MRD+ (median, [range])	0.26 [0.012–36]		0.22 [0.026–36]		0.30 [0.012–22.4]		0.91

NCI, National Cancer Institute; WBC, white blood cell; CNS, central nervous system; EOI MRD, end of induction minimal residual disease (bone marrow).

^aPearson chi-square, Fisher exact test, or K-S test; significance set at P < 0.05 (bolded).

^bFavorable includes “double trisomy” 4+10 (n = 45) and ETV6-RUNX1 (n = 69). Unfavorable includes hypodiploid (<44 chromosomes, n = 1), rMLL (n = 3), iAMP21 (n = 0).